http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#Head http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#assertion http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#provenance http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#pubinfo http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#assertion http://purl.obolibrary.org/obo/DOID_4450 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_4450 http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB01268 http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#association http://www.w3.org/2000/01/rdf-schema#label sutent is a kinase inhibitor indicated for the treatment of gastrointestinal stromal tumor gist after disease progression on or intolerance to imatinib mesylate 1 1 the treatment of advanced renal cell carcinoma rcc 1 2 the adjuvant treatment of adult patients at high risk of recurrent rcc following nephrectomy 1 3 the treatment of progressive well differentiated pancreatic neuroendocrine tumors pnet in patients with unresectable locally advanced or metastatic disease 1 4 sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate sutent is indicated for the treatment of advanced renal cell carcinoma sutent is indicated for the adjuvant treatment of adult patients at high risk of recurrent rcc following nephrectomy sutent is indicated for the treatment of progressive well differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB01268 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#provenance http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#pubinfo http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#sig http://purl.org/nanopub/x/hasSignature IbmxHLDhkLeZ/iUe35feVHnJ++MfzrsM6Y5xa+lPm7jX1M8IyZo99G/LnVLL3f4trWSzYfQLGPzMyUvYJ556I+yoTH6OB5seG+1TxbbdxHMzBnUDD2a/6qkfce7i1oIikxZVyXDQe/5+A92FzH2iPnTu2mcoye7eTyviIILLzVs= http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY http://purl.org/dc/terms/created 2021-07-03T11:43:08.227+02:00 http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs